UBS lowers McCormick stock price target to $71 on tariff concerns

UBS has lowered its price target on McCormick (MKC) to $71 from $79, maintaining a Neutral rating, ahead of its fiscal third-quarter earnings, citing an expected deceleration in organic sales growth to 1.3% (below the 1.8% consensus) and incremental tariff headwinds posing downside risk to fiscal year 2026 estimates. While market concerns regarding Flavor Solutions growth and tariffs appear largely priced into the stock following recent declines, and McCormick is strategically increasing its Mexican joint venture stake, UBS does not foresee a meaningful positive catalyst from the upcoming earnings, noting the current 23.35x P/E is high relative to near-term growth.

Analysis

McCormick & Company (MKC) faces a cautious near-term outlook, as highlighted by UBS's decision to lower its price target to $71.00 from $79.00 while maintaining a Neutral rating ahead of the fiscal third-quarter report. The firm anticipates a sequential deceleration in organic sales growth to 1.3%, falling short of the 1.8% Street consensus, driven primarily by concerns over incremental tariff headwinds that pose a downside risk to fiscal year 2026 estimates. This perspective suggests the upcoming earnings are unlikely to serve as a meaningful positive catalyst. The stock's low-double-digit decline since its last report, underperforming the packaged food sector, indicates that the market has already priced in some of these headwinds. Despite the stock trading at a forward P/E of approximately 20x, in line with 2014-2016 levels, its current P/E of 23.35x is noted as high relative to near-term growth prospects. Contrasting this cautious short-term view are McCormick's strategic long-term initiatives, including a $750 million investment to increase its stake in a Mexican joint venture to 75%—a move endorsed by TD Cowen—and its 101st consecutive year of dividend payments, demonstrating a commitment to capital deployment.

Key Decisions for Investors

• Investors should approach the upcoming Q3 earnings call with caution, as analyst expectations point to decelerating sales growth and tariff pressures, creating a high bar for a positive stock reaction.
• Given the stock's valuation is considered high relative to near-term growth, it is critical to scrutinize management's updated guidance on the impact of tariffs and organic sales trends before increasing exposure.
• Long-term investors may focus on the strategic rationale behind the increased investment in the Mexican joint venture, but should monitor the impact of its debt and cash financing on the balance sheet.